TaiGen, Zhejiang Medicine sales and marketing update

TaiGen granted Zhejiang Medicine exclusive rights to commercialize and manufacture nemonoxacin in China, excluding Hong Kong and Macau. TaiGen will receive an $8 million upfront payment and is eligib...